Bidis and smokeless tobacco are the cheapest, least taxed and most commonly used tobacco products in India. They are highly addictive and high in carcinogens. They cause a broad spectrum of diseases; yet awareness about their ill-effects is low. Smokeless tobacco products containing arecanut, e.g. gutka and mawa, are especially addictive and carcinogenic.

The hookah, a waterpipe, originated in India and became popular for smoking tobacco. It spread elsewhere and acquired other names like nargile, shisha, goza and hubble-bubble, before its popularity declined in India. A resurgence of hookah smoking is occurring in India and around the world, and is being promoted as safer than cigarette smoking.

Chronic exposure to traffic-related air pollution (TRAP) may contribute to premature mortality, but few studies to date have addressed this topic. This study assessed the association between TRAP and mortality in Toronto, Ontario, Canada.

Smoking causes lung cancer and is implicated in a dozen other cancers, but scientists have generally dismissed its importance in breast cancer, saying it plays little role, if any.

In 1971, flush with the nation

In Xuanwei County, China, unvented indoor coal burning is strongly associated with increased risk of lung cancer and chronic obstructive pulmonary disease. However, the impact of coal burning and stove improvement on risk of pneumonia is not clear. The researchers conducted a retrospective cohort study among all farmers born 1917 through 1951 and living in Xuanwei as of 1 January 1976.

Air pollution is an important determinant of population health. In an analysis that correlates reductions in fine particulate matter (i.e., particles less than 2.5

In response to the health risks posed by asbestos exposure, some countries have imposed strict regulations and adopted bans, whereas other countries have intervened less and continue to use varying quantities of asbestos.

The most complete survey yet of the genes which go wrong when lung cancer takes hold has been carried out by US researchers.

The cancer drug Erbitux prolonged the lives of patients with advanced lung cancer by five weeks, according to a new clinical study described as an important gain for such individuals. "Patients with advanced NSCLC (non-small cell lung cancer) have limited treatment options and life expectancy is short, so the survival increase shown in this study is an important step for these patients,' said Robert Pirker of the Medical University of Vienna, a lead investigator in the study.